Lowenstein Sandler represented Regulatory Professionals, Inc. (RPI) in its acquisition by Premier Research. RPI provides regulatory expertise and solutions to the pharmaceutical, biopharmaceutical, and medical device industries. Premier Research is a prominent clinical development service provider that helps biotech and specialty pharma innovators transform life-changing ideas into new medicines.
The acquisition gives RPI greater market share as well as access to resources that complement its regulatory service offering, such as data management and biostatistics, clinical development, safety management, and other critical disciplines. Acquiring RPI enables Premier Research to offer regulatory solutions to biotechnology, pharmaceutical, and medical device companies. Those services include regulatory guidance, document preparation for submission to federal agencies, and management of the submission process on behalf of clients seeking to bring new drugs and medical devices to market.
RPI provides strategic advice, regulatory planning, and a full range of eCTD submission services in order to help clients advance the development and registration of their products in worldwide markets. Founded in 1995, RPI employs more than 40 professionals with extensive regulatory experience across the complete product life cycle, across product types, and covering a wide range of fast-growing therapeutic areas, including oncology, neurology, cardiovascular, and dermatology. RPI's clients are small and midsize companies seeking guidance and support as they move their products into and through development, as well as larger companies seeking to fill resource gaps within their in-house regulatory departments.
Lowenstein Sandler served as legal counsel to RPI; the company was also advised by Edgemont Capital Partners and KPMG LLP.